As drug development becomes more complex, integrated innovation partners are proving essential to advancing programs from concept to clinic. Tune in to biotech leaders, pharma R&D experts, and Syngene’s senior team for a powerful panel discussion on how high-performing partnerships drive speed, quality, and valuation.
Why Watch This Webinar?
- Identify development partners that accelerate timelines and reduce risk
- Explore integrated models that improve ROI across the pipeline
- Gain insights from real-world case studies and performance benchmarks
Key Speakers
Kenneth Barr
Kenneth Barr, PhD, is an expert in synthetic organic and organometallic chemistry with 30 years in drug discovery. He has held leadership roles at Abbott Labs, Merck Sharp & Dohme, Amplyx Pharmaceuticals, and Sunesis, where he led global R&D operations and CRO alliances.
Catherine Tucker
With 20 years in drug discovery, development, and commercialization, Catherine has led strategy and business development across pharma, biotech, and AI-driven companies, including BenevolentAI. She holds degrees in biochemistry, clinical pharmacology, and an MBA.
Kush M. Parmar, M.D, Ph.D.
Dr. Kush Parmar is a Managing Partner at 5AM Ventures and serves on advisory boards for Harvard Medical School, Penn Medicine, and Princeton. A trained physician-scientist, he completed his M.D/Ph.D. at Harvard and has deep expertise in genetics, biotechnology, and venture investment.
